Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

Cell Communication and Signaling

Short Report

Jörn Dengjel¹  Christine Gretzmeier²  Zehan Hu²  Tilman Brummer³  Julia Ellermann⁴  Sebastian Halbach⁵  Franziska U. Wöhrle⁶ 

[1] Freiburg Institute for Advanced Studies (FRIAS), and Center for Biological Systems Analysis (ZBSA), University of Freiburg, Freiburg, Germany;BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany;Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany;Freiburg Institute for Advanced Studies (FRIAS), and Center for Biological Systems Analysis (ZBSA), University of Freiburg, Freiburg, Germany;Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany;Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, Freiburg, Germany;BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany;Deutsches Konsortium für Translationale Krebsforschung (DKTK) and Comprehensive Cancer Center Freiburg, University Medical Center, Freiburg, Germany;Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, Freiburg, Germany;Faculty of Biology, University of Freiburg, Freiburg, Germany;Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, Freiburg, Germany;Faculty of Biology, University of Freiburg, Freiburg, Germany;Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany;Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, Freiburg, Germany;Faculty of Biology, University of Freiburg, Freiburg, Germany;Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany;BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany;

关键词: Chronic myeloid leukemia;    CML;    TKI resistance;    Imatinib;    Sorafenib;    Axitinib;    Ponatinib;    Gab2;    Hyperactive Lyn;    Bcr-Abl;   

DOI  :  10.1186/s12964-016-0129-y

 received in 2015-12-22, accepted in 2016-02-16,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundChronic myeloid leukemia (CML) is driven by the fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML therapy. Nevertheless, about 20 % of CMLs display primary or acquired TKI resistance. TKI resistance can be either caused by mutations within the Bcr-Abl kinase domain or by aberrant signaling by its effectors, e.g. Lyn or Gab2. Bcr-Abl mutations are frequently observed in TKI resistance and can only in some cases be overcome by second line TKIs. In addition, we have previously shown that the formation of Gab2 complexes can be regulated by Bcr-Abl and that Gab2 signaling counteracts the efficacy of four distinct Bcr-Abl inhibitors. Therefore, TKI resistance still represents a challenge for disease management and alternative therapies are urgently needed.FindingsUsing different CML cell lines and models, we identified the clinically approved TKIs sorafenib (SF) and axitinib (AX) as drugs overcoming the resistance mediated by the Bcr AblT315I mutant as well as the one mediated by Gab2 and LynY508F. In addition, we demonstrated that AX mainly affects the Bcr-Abl/Grb2/Gab2 axis, whereas SF seems to act independently of the fusion kinase and most likely by blocking signaling pathways up- and downstream of Gab2.ConclusionWe demonstrate that SF and AX show potency in various and mechanistically distinct scenarios of TKI resistance, including Bcr-AblT315I as well as Lyn- and Gab2-mediated resistances. Our data invites for further evaluation und consideration of these inhibitors in the treatment of TKI resistant CML.

【 授权许可】

CC BY   
© Halbach et al. 2016